Drug Trial Radar · NCT02201004
TOFO Insulin Combination Trial
Last checked: Nov 19, 2026Latest source record: Oct 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Jun 2014
Primary completion
Jan 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Kowa Company, Ltd.
- First posted
- Jul 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: To assess the effects of tofogliflozin on glycemic control in comparison to placebo as an add-on treatment to insulin treatment in terms of glycated hemoglobin (HbA1c) reduction over a period of 16 weeks in patients with type 2 diabetes mellitus. To assess the safety of tofogliflozin in combination with insulin treatment throughout 52 weeks. Secondary Objectives: To assess the effects of tofogliflozin in comparison to placebo on: * Body weight * Fasting plasma glucose (FPG) * Postprandial plasma glucose (PPG) To assess the long term safety and tolerability of tofogliflozin.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TOFOGLIFLOZIN CSG452Drug
Pharmaceutical form:tablet Route of administration: oral
insulinDrug
Pharmaceutical form:solution Route of administration: subcutaneous
placeboDrug
Pharmaceutical form:tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c from baselineTime frame: 16 weeks after first intake of investigational product
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 392-028
Adachi-ku, Japan
Investigational Site Number 392-007
Atsugi-shi, Japan
Investigational Site Number 392-026
Chuoh-ku, Japan
Investigational Site Number 392-021
Fukuoka, Japan
Investigational Site Number 392-002
Ichihara-shi, Japan
Investigational Site Number 392-012
Iruma-shi, Japan
Investigational Site Number 392-003
Kawaguchi-shi, Japan
Investigational Site Number 392-014
Kitakyusyu-shi, Japan
Investigational Site Number 392-027
Kobe, Japan
Investigational Site Number 392-004
Koga-shi, Japan
Investigational Site Number 392-022
Kunitachi-shi, Japan
Investigational Site Number 392-019
Kurume-shi, Japan
Investigational Site Number 392-001
Kyoto, Japan
Investigational Site Number 392-024
Kyoto, Japan
Investigational Site Number 392-006
Matsudo-shi, Japan
Investigational Site Number 392-008
Mito, Japan
Investigational Site Number 392-030
Musashino-shi, Japan
Investigational Site Number 392-029
Okayama, Japan
Investigational Site Number 392-017
Ōtsu, Japan
Investigational Site Number 392-011
Sagamihara-shi, Japan
Investigational Site Number 392-020
Sakaishi, Japan
Investigational Site Number 392-010
Sapporo, Japan
Investigational Site Number 392-016
Sendai, Japan
Investigational Site Number 392-018
Shinjuku-ku, Japan
Investigational Site Number 392-005
Shizuoka, Japan
Investigational Site Number 392-031
Suita-shi, Japan
Investigational Site Number 392-015
Sumida-ku, Japan
Investigational Site Number 392-023
Sunto-gun, Japan
Investigational Site Number 392-013
Tokorozawa-shi, Japan
Investigational Site Number 392-025
Yokohama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.